TNFRSF10A and type 1 diabetes mellitus: We first asked whether TIGIT+KLRG1+ TEX are selectively modulated in DR4 T1D subjects, examining the teplizumab (anti-CD3) trial in individuals at risk for T1D since DR4 was previously identified as a weak correlate of response (15).